Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study

Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study

Abstract Aims/Introduction Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long‐term treatments are available. Methods This was an investigator‐initiated multicenter prospective intervention study in which ipragliflozin (50 mg) was administered once daily...

Full description

Bibliographic Details
Main Authors: Ikuro Matsuba, Takehiro Kawata, Kotaro Iemitsu, Taro Asakura, Hikaru Amemiya, Masashi Ishikawa, Syogo Ito, Mizuki Kaneshiro, Akira Kanamori, Akira Kubota, Kazuaki Shinoda, Masahiko Takai, Tetsuo Takuma, Masahiro Takihata, Hiroshi Takeda, Keiji Tanaka, Yoko Matsuzawa, Hideo Machimura, Fuyuki Minagawa, Nobuaki Minami, Atsuko Mokubo, Masaaki Miyakawa, Yasuo Terauchi, Yasushi Tanaka
Format: Article
Language:English
Published: Wiley 2020-09-01
Series:Journal of Diabetes Investigation
Subjects:
Diabetic nephropathy
Ipragliflozin
Sodium–glucose cotransporter 2 inhibitor
Online Access:https://doi.org/10.1111/jdi.13248

Internet

https://doi.org/10.1111/jdi.13248

Similar Items